Persistence of hepatic hepatitis B virus after serological clearance of HBsAg with autologous peripheral stem cell transplantation

George K K Lau, Pui Chee Wu, Raymond Liang, Siu Tsan Yuen, Wei Ling Lim

Abstract

Delayed clearance of hepatitis B surface antigen was previously reported in a 38 year old woman after high dose chemotherapy with autologous peripheral blood stem cell rescue. Sixteen months later, this patient remained hepatitis B surface antigen negative, hepatitis B surface antibody positive, and serum hepatitis B DNA negative by polymerase chain reaction. Serial liver biopsies (one at hepatitis B e antigen positive stage, one at hepatitis B e antibody positive stage, and one at hepatitis B surface antigen negative and hepatitis B surface antibody positive stage) showed a gradual resolution of the inflammatory activity with loss of hepatitis B e antigen and then hepatitis B surface antigen in the serum. However, the degree of fibrosis, though mild, remained the same. With the serological clearance of hepatitis B surface antigen, a small amount of hepatitis B virus DNA was still detectable in the nuclei of liver cells.

Keywords: hepatitis B virus; lymphoma; high dose chemotherapy; peripheral blood stem cell; virus persistence

Chronic hepatitis B infection (HBV) is a serious global health problem affecting approximately 300 million individuals. Of these, 20 to 40 per cent are likely to die of cirrhosis or hepatocellular carcinoma. Seventy five per cent of the HBV virus carriers are Chinese and most of them acquire the infection perinatally. Unfortunately, spontaneous loss of hepatitis B surface antigen (HBsAg) is a rare occurrence. The cause of viral persistence is largely unknown. Previously, we reported our preliminary observation on the delayed clearance of HBsAg in a 38 year old woman 33 months after high dose chemotherapy with autologous peripheral blood stem cell rescue. Sixteen months after this serological clearance of HBsAg, she remains HBsAg negative, hepatitis B surface antibody (HBsAb) positive, and HBV DNA negative in serum by both dot hybridisation and polymerase chain reaction (PCR). Recently, it was found that traces of HBV are often detectable in the blood for many years after clinical recovery from acute hepatitis. In this study, we examined the serial changes in liver histology before and after recovery from chronic HBV infection in this patient, and the hepatic expression of HBV markers.

Case report

A 40 year old Chinese woman, known to be HBsAg positive since 1982, was diagnosed as having non-Hodgkin's lymphoma in December 1984. At that time, she was HBsAg positive, hepatitis B e antigen (HBeAg) positive, and serum HBV DNA positive (by dot hybridisation), with normal liver function tests (serum alanine aminotransferase 17 IU/l). Seven courses of chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by local radiotherapy were given. This resulted in complete remission of the lymphoma.

During the treatment period (in December 1985), she had an episode of HBV reactivation (peak serum aminotransferase 1932 IU/l) and liver biopsy at that time showed chronic active hepatitis (fig 1A). There was marked piecemeal plus bridging necrosis, marked intralobular degeneration and focal necrosis, marked portal inflammation, and fibrous portal expansion. The histological activity index (HAI) score was 15 (table 1). Immunohistochemistry showed < 1% of hepatocytes stained positive for both HBsAg and hepatitis B core antigen (HbcAg). HBV DNA was positive by in situ hybridisation in the cytoplasm of 75% of the hepatocytes. The patient had an uneventful recovery.

In February 1986, she had a lymphoma recurrence in the right submandibular region and was given another six courses of chemotherapy consisting of epirubicin, vincristine, cytarabine, prednisolone, and bleomycin, resulting in a second complete remission. During this second course of chemotherapy, there was no HBV reactivation and the patient remained HBsAg positive, HBeAg positive, and HBV DNA positive by dot hybridisation. In April 1986, she seroconverted from HBeAg positive to HBeAb positive, with disappearance of serum HBV DNA by dot hybridisation, though positivity by PCR persisted.

In December 1990, the lymphoma recurred in her left cervical lymph nodes. She was given chemotherapy consisting of ifosfamide, methotrexate, and etoposide, resulting in a third complete remission. There was no HBV reactivation during this third course of chemotherapy and she remained HBsAg positive, HBeAb positive, and serum HBV DNA negative by dot hybridisation but positive by PCR. Liver biopsy in March 1991 showed
chemotherapy consisting of cyclophosphamide, carmustine, and etoposide with autologous peripheral stem cell rescue was given in February 1992. The peripheral blood stem cells were collected after granulocyte colony stimulating factor (G-CSF) mobilisation. The post-transplantation course was eventful apart from grade 1 regimen related liver toxicity from day 20 to day 25 (peak bilirubin 33 μmol/l). Her liver function tests remained in the normal range thereafter. On day 379, she was HBsAg positive, HBeAg negative, HBeAb positive, and HBV DNA negative by dot hybridisation but positive by PCR. In November 1994 (33 months after the high dose therapy), the patient seroconverted to become HBsAg negative, HBeAb positive, and serum HBV DNA negative by both dot hybridisation and PCR.

A third liver biopsy was performed on 19 March 1996. The histology showed only mild fatty changes with no piecemeal necrosis, very mild intralobular degeneration, very mild portal inflammation, and fibrous portal expansion (fig 1D). There was no HBsAg and HBeAg staining. However, liver cell nuclei were still positive (<5% of cells) by in situ hybridisation, and the liver was positive for HBV DNA by PCR.

**Methods used**

**HEPATITIS SEROLOGY ASSAYS, SERUM AND TISSUE HBV DNA**

Hepatitis B serological markers—HBsAg (Auszyme, monoclonal), HbsAb, HBeAg, HBeAb; hepatitis C virus antibody (EIA II), hepatitis D virus antibody, and human immunodeficiency antibody—were all tested using commercially available enzyme immunoassays (Abbott Laboratories, Chicago, Illinois, USA).

Clearance of HBsAg was confirmed by retesting using the polyclonal assay (Murex, Dartford, England). Serum HBV DNA was detected using dot hybridisation. HBV DNA was extracted from paraffin embedded liver tissue as described by Shindo et al. Nested PCR assay for the detection of serum extracted and tissue extracted HBV DNA was performed using primer sets from the surface antigen and the core antigen coding regions.

**HISTOLOGICAL ASSESSMENT, IMMUNOHISTOCHEMISTRY, AND IN SITU HYBRIDISATION**

The liver biopsies were assessed under code by a pathologist (PCW) who had no prior knowledge of the patient’s clinical data or of the chronological order of the biopsy specimens. Chronic hepatitis was graded and staged using the histological activity index (HAI). The amount of HBV antigen in the liver biopsy samples was determined by standard immunohistochemistry (HBsAg, monoclonal antibody, Biogenex, San Ramon, California, USA; HBeAg, polyclonal, Dako, Carpentia, California, USA) on paraffin sections. The PAP kit (Amersham, Chicago, Illinois, USA) was employed, with peroxidase as the marker and diaminobenzidine as the substrate. Hepatic

![Figure 1](A) Liver section showing marked portal inflammation with profound piecemeal and bridging necrosis (trichrome, x70). (B) Liver section showing mild portal inflammation and fibrous portal expansion, and mild piecemeal and focal necrosis (haematoxylin and eosin, x110). (C) Immunohistochemical staining showing 30% of hepatocytes positive for hepatitis B surface antigen (x110). (D) Liver section showing only mild portal inflammation and fibrous portal expansion with no piecemeal or focal necrosis (haematoxylin and eosin, x175).

### Table 1  Histological changes of serial liver biopsies

<table>
<thead>
<tr>
<th>Date of liver biopsy</th>
<th>2347 days before BMT</th>
<th>339 days before BMT</th>
<th>1484 days after BMT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histological variables</td>
<td>6</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Periportal (+) bridging necrosis (0-10)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Interlobular degeneration and focal necrosis (0-4)</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Portal inflammation (0-4)</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Fibrosis (0-4)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total histological activity index score</td>
<td>15</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Hepatic expression of HBV</td>
<td>&lt;1/&lt;1</td>
<td>30/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbsAg+/HBeAg+ (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In situ hybridisation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV DNA+ (%)</td>
<td>75/0</td>
<td>50/25</td>
<td>0/5</td>
</tr>
<tr>
<td>Cytoplasm/nucleus</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

BMT, bone marrow transplant; HBV, hepatitis B virus; HbsAg, hepatitis B surface antigen; HBeAG, hepatitis B e antigen; PCR, polymerase chain reaction.
HBV DNA was detected by in situ hybridisation as described previously.9

Discussion

The patient we report here has been followed up at our clinic for more than 11 years (seven years before bone marrow transplantation and more than four years afterwards). This is the first documented report on the serological clearance of HBsAg following high dose chemotherapy and peripheral blood stem cell rescue. The patient has a definite history of chronic hepatitis B, as evidenced by previous serology and histology. The mechanism for her loss of HBV viral markers (HBsAg and HBV DNA) is unknown. Loss of HBsAg is probably related to the high dose chemotherapy and autologous peripheral blood stem cell infusion, as the chance of spontaneous loss of HBsAg is extremely low, especially in Chinese (0.1% to 0.8%).

No matter what mechanism was involved, this report suggests that the cause of HBV persistence is not clonal deletion but clonal suppression, as only autologous cells were involved.7 Hepatitis B e seroconversion occurred more than 300 days before the autologous bone marrow transplant. This was accompanied by lowering of HBV DNA in serum, which could not be detected by dot hybridisation but only by PCR. Histologically, even at this stage there was already marked reduction in necroinflammatory activity. This lowered HBV DNA level might have helped the subsequent clearance of HBsAg after autologous bone marrow transplantation. This is in analogy to the use of interferon in treating HBV, where a low HBV DNA level favours response. Similarly, it was our recent observation that a high pre-bone marrow transplant HBV DNA viral load might have prevented one of our autologous bone marrow transplant patients from clearing HBsAg after reception of HBsAb positive marrow.10

The loss of HBsAg occurred 33 months after the autologous bone marrow transplantation. This kind of delayed clearance has also been reported in patients treated with interferon. With seroconversion from HBsAg to HBsAb and then from HBsAg to HBsAb, there was marked resolution of inflammatory components (marked piecemeal necrosis and bridging necrosis observed in the initial liver biopsy). However, the fibrous portal expansion, though mild, remained the same throughout the course. The histological picture probably represented an inactive burned out form of chronic active hepatitis.9

Though the patient is HBsAg negative and HBsAb positive, HBV DNA is still detectable in the liver tissue by in situ hybridisation and PCR. This low level of HBV, which persisted in the liver, probably represents active virus rather than integrated, non-replicative forms of genome. First, recrudescence of hepatitis B has been reported in HBsAg negative patients who have been treated with cancer chemotherapy, immunosuppressive regimens, or liver transplantation.10 Second, there have been several reports of transmission of hepatitis B by blood donations from HBsAg negative patients.11 Third, it has been shown that resolution of HBV infection with the development of HBsAb does not necessarily mean complete eradication of the virus. Recently, it was found that HBV specific cytotoxic T lymphocytes can be present as acute stage precursors long after recovery, displaying an activated phenotype (HLA-DR, CD69), and can coexist with trace amounts of HBV DNA. These data suggest that the hepatitis B virus is controlled by the cellular and humoral immune response rather than being completely eradicated after resolution of acute and chronic hepatitis B infection.12

References

1 Lok ASF. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992;10:46–52.